Imbrium Signs a License Agreement with TetraGenetics for its TetraExpress Technology

 Imbrium Signs a License Agreement with TetraGenetics for its TetraExpress Technology

Imbrium Signs a License Agreement with TetraGenetics for its TetraExpress Technology

Shots:

  • TetraGenetics to receive $25M upfront, $248M milestones as contingent payments, FTE payments and royalties upto 7% on sales of product. Imbrium to get license for TetraGenetics’ TetraExpress Technology with an option to develop therapies post IND submission for pain and autoimmune disorders
  • The focus of the agreement is to develop non-opioid therapies with advancement of mAbs targeting ion channels utilizing TetraExpress technology for the treatment of pain conditions
  • TetraExpress technology is an Ab discovery platform for developing biologics targeting ion channel for autoimmune diseases and pain

Click here to read full press release/ article | Ref: Imbrium Therapeutics | Image: MassBio

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post